RE: Trades 814 @ 1650hrs24 Nov 2025 20:24
From AI - my input was ' Immupharma disappoints the market'
it states no due diligence yet started. Not sure where it got that from but it's just another humdinger for Tim to hang his professional hat on as a corporate leader. LMFAO. If no DD has commenced yet then there won't be a deal for several months, especially has Tim has now so kindly stressed they are taking the methodical approach rather than one of speed. Gawd help IMM share holders. Just how low could this go? If there's silence come end of January then I really think it could end up right back at 2p.
ImmuPharma has recently disappointed the market due to an announcement that a potential deal for its drug Lupuzor will not be reached by the previously stated end of 2025 deadline, leading to a drop in its share price.
Reasons for Disappointment
Delayed Deal: The company had repeatedly indicated that a commercial deal for its lead drug candidate, Lupuzor (for the treatment of lupus), was expected by the end of 2025. A recent regulatory news service (RNS) update clarified that while discussions are ongoing, no deal has been agreed upon, and due diligence is yet to commence, pushing the timeline into 2026.
Perceived Lack of Transparency: Some shareholders expressed frustration and a lack of trust in Chairman Tim McCarthy, feeling that he had "over promised" and shifted the narrative from a "deal by 2025" to a "stated aim 2025" to an indefinite timeline, resulting in damaged investor sentiment.
Share Price Impact: The news has caused the share price to drop, with some shareholders exiting their positions and others predicting further falls, reflecting the market's negative reaction to the delay and uncertainty.